ClinicalTrials.gg
Active, not recruitingNCT06144892Updated Oct 16, 2026

The Comfort of Proactive Sleep Apnea Therapy

An interventional study of Proactive Therapy in Obstructive Sleep Apnea and Sleep Apnea, sponsored by NovaResp Technologies Inc. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by NovaResp Technologies Inc · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now Active, not recruitingFirst site in Canada+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.

Planned enrollment
55th of 102
50 · median 60
Started
2024
with 5 others
No phase
70 of 133
9 open now
Primary completion
2027-12
later than 20 of 30 live
Registered
115th of 133
by date
Lead sponsor
3 of 133
NovaResp Technologies Inc

Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 55th largest by planned enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2024, is one of 70 with no phase, reaches primary completion later than 20 of the 30 other live ones, and was the 115th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sleep Apnea, Obstructive with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare in OSA patients who regularly adhere to CPAP therapy. The main question[s] it aims to answer are:

  • To assess if proactive therapy can effectively treat OSA with lower mean therapy pressure compared to conventional APAP therapy
  • To compare user comfort between proactive therapy and conventional APAP therapy

Participants will undergo the conventional APAP therapy and the new proactive therapy.

Researchers will compare nights in which conventional APAP was used and nights in which proactive therapy was used to see if patients were treated with lower pressures and effectively.

Read the detailed description

This is a blinded, randomised, crossover, study on patients diagnosed with obstructive sleep apnea who regularly adhere to APAP therapy. Data collection will span 23 consecutive nights for each participant. Participants will use a modified APAP device for 2 periods of 9 nights each, separated by 5 nights in which participants will use their personal APAP device. The modified APAP device is switchable between two therapy modes: a) proactive therapy, and b) conventional APAP therapy. Treatment for the 2 periods will be randomly assigned, with one period as the test period where the proactive therapy is used every night for 9 consecutive nights, and the other as the control period where their conventional APAP therapy (i.e., the participant's regular therapy but on the modified device) is used every night for 9 consecutive nights. Participants will be blinded to the therapy they are receiving during the test and control period. Data will be collected by the modified PAP device and at-home sleep apnea test ring.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be a current CPAP user
  • Must have used a PAP device for more than 4 months.
  • Before the first night of the study, participant must be willing to lend their personal PAP device for inspection in order for the study coordinator to transfer their PAP therapy settings to one of our modified PAP devices.
  • Must be willing to wear the sleep diagnostic ring throughout each night of the study for the entire study duration (i.e., the full 23 days).
  • Must be willing to have their CPAP SD memory card analyzed to determine their mean pressure and excess leak rate history
  • Must be free of flu-like illness or any upper tract infection symptoms at the time of data collection.

Exclusion criteria

Exclusion Criteria:

  • Subjects actively using bi-level PAP or require oxygen therapy.
  • Inspection of the participant's CPAP SD card data shows that history of highly frequent excess leak during therapy. Exclusion due to high leak will be determined on a case-by-case basis.
  • History of severe cardiovascular disease, including Class III or IV heart failure, CAD with angina, or MI/stroke within past 6 months.
  • Subjects who are medically complicated or who are medically unstable (i.e., cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness)
  • Potential sleep apnea complications that in the opinion of the clinician may affect the health and safety of the participant.
  • Inability or unwillingness of individual to give written .
  • Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, New York Heart Association class III or IV heart failure, recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months), persistent uncontrolled hypertension despite medication use, active psychiatric disease, and coexisting non-respiratory sleep disorders that would confound functional sleep assessment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention first

    Patients will undergo proactive therapy first, followed by the buffer period, and finally the conventional APAP therapy.

    Device: Proactive Therapy

  • Experimental
    Control first

    Patients will undergo the conventional APAP therapy first, followed by the buffer period, and finally the proactive therapy.

    Device: Proactive Therapy

Interventions

  • DeviceProactive Therapy

    Uses AI to make predictions and preventions of future apneic events.

06

What researchers measure

Primary outcomes

  1. Mask pressure

    Calculated as the mean pressure throughout the night.

    Time frame: 18 nights

Secondary outcomes

  1. Apnea-Hypopnea Index

    Calculated as the mean number of apnea and hypopnea events throughout the night, in events/hr.

    Time frame: 18 nights

  2. Comfort score

    Questionnaire that measures comfort of therapy.

    Time frame: 18 nights

  3. Sleepiness self-assessment

    Patients will be requested to fill out a questionnaire to help evaluate their sleepiness after the treatment period and control period

    Time frame: 18 nights

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 45 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2024 → Dec 2027 and completion Jul 2024 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 22, 2023
StartActual
Mar 25, 2024
Primary completionEst.
Dec 30, 2027was Jul 2024
CompletionEst.
Dec 30, 2027was Jul 2024
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 16, 2026
Sites
1 site added — first site in Canada
Show site
  • NovaResp Technologies · Halifax, Canada
Oct 16, 2026
Primary completion
Jul 1, 2024→Dec 30, 2027
Oct 16, 2026
Study completion
Jul 1, 2024→Dec 30, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Active, not recruiting
    1 site added — first site in Canada
    Show site
    • NovaResp Technologies · Halifax, Canada
    Primary completion Jul 1, 2024→Dec 30, 2027
    Study completion Jul 1, 2024→Dec 30, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06144892
Lead sponsor
NovaResp Technologies Inc
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Mar 25, 2024
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion